Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This refers to a specific postoperative analgesic protocol utilizing patient-controlled intravenous analgesia (PCIA) with tramadol, as implemented in clinical research at Gaziosmanpasa Research and Education Hospital. Tramadol is a centrally acting synthetic opioid analgesic that exerts its effects through a dual mechanism of action: it acts as a weak agonist at mu-opioid receptors and inhibits the neuronal reuptake of norepinephrine and serotonin. In the context of the hospital's protocol (e.g., for laparoscopic cholecystectomy), the PCIA regimen typically involves a 20 mg bolus of intravenous tramadol with a 20-minute lockout time, a 4-hour limit of 100 mg, and a 24-hour limit of 400 mg. This method allows patients to self-administer small doses of analgesia to manage acute postoperative pain effectively.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on patient controlled intravenous analgesia-Gaziosmanpasa Research and Education Hospital.